Category Archives: Blog

AQP4: From Water Channel to a Potential Drug Target in Neurological Diseases

Aquaporins (AQPs) are best known as membrane channels that transport water. As research has advanced, however, their biological significance has expanded far beyond basic water transport to include cerebral edema, autoimmunity, brain fluid clearance, and neurodegenerative diseases. Among the AQP family, aquaporin-4 (AQP4) has attracted particular attention because of its distinctive distribution and complex regulation in the central nervous system (CNS).

Blog 2026-09-13

Major Biopharma Deals in July-August 2026: ADCs, Autoimmune Disease & Emerging Platforms

Global biopharma dealmaking remained active throughout July and August 2026, spanning major acquisitions, licensing agreements and platform collaborations. ADCs, autoimmune and metabolic diseases, CNS programs, RNA technologies, AI-driven drug discovery and in vivo CAR-T were among the most active areas.

Blog 2026-09-08

EMP2/XMP: From a Membrane Protein Regulator to a Potential Therapeutic Target for Cancer

Epithelial Membrane Protein 2 (EMP2) is emerging as a promising membrane protein target in cancer therapy. Recent studies have explored EMP2-targeting strategies, including siRNA delivery systems, monoclonal antibodies, and ADCs, demonstrating potential in suppressing tumor progression and modulating the tumor immune microenvironment.

Blog 2026-08-21

Biotinylated Full-Length Membrane Proteins for Drug Discovery

DIMA Biotechnology provides in-stock biotin-labeled full-length membrane proteins prepared using Nanodisc technology. Expressed in mammalian cells to preserve native conformation and biological function, these proteins effectively support SPR/BLI binding analysis, antibody discovery, CAR-T positivity assessment, and research on challenging membrane protein targets.

Blog 2026-07-29

Up to $12.36 Billion! A Roundup of Global Biopharma Deals in June 2026

June 2026 Biopharma Deal Wave: Multibillion-Dollar M&A Surges Alongside Licensing Deals for Cutting-Edge Technologies Such as T-Cell Engagers and RNA Editing. Chinese Pharmaceutical Companies Are Expanding Their Global Partnerships from Single-Asset Licensing to Multi-Target Platform Deals, While Oncology Continues to Lead and Attract Strong Global Investor Interest.

Blog 2026-07-20

Advances in STEAP1-Targeted Drug Development: T-Cell Engager Enters Phase III as ADC and CAR-T Programs Advance

The first STEAP1-targeted therapy, Xaluritamig, has delivered promising Phase III clinical results, achieving a PSA50 response rate of 59%. Multiple therapeutic modalities，including bispecific ADCs, CAR-T cells, and trispecific T-cell engagers are advancing rapidly and demonstrating strong potential, ushering in a new era of targeted therapy for prostate cancer.

Blog , 2026-07-10

World’s First CAR-T Therapy for Solid Tumors Approved: How Can CLDN18.2 CAR Positivity Be Detected More Accurately?

The approval of the world’s first CAR-T therapy for solid tumors not only marks a new milestone in CAR-T treatment, but also brings CLDN18.2 into the spotlight as a highly attractive target. During CAR-T development, accurately and reliably detecting CAR positivity is an important foundation for evaluating product quality and functional performance.

Blog 2026-07-05

2026 ASCO Target Review (Part III): Small-Molecule Targeted Therapy and Precision Oncology

Classic targets such as EGFR, RET, RAS, ER, and AR continue to evolve, while precision oncology advances from identifying driver mutations toward earlier intervention and more refined patient stratification.

Blog 2026-06-24

2026 ASCO Target Review (Part II): Bispecific and Multispecific Antibodies and Immunotherapy Combinations

Bispecific antibody development is evolving beyond simply combining two targets, with T-cell engagers, PD-1×VEGF, PD-1×CTLA-4, and 4-1BB-based approaches emerging as key drivers of next-generation immuno-oncology innovation.

Blog 2026-06-24

2026 ASCO Target Review (Part I): ADCs

Beyond HER2 and TROP2, emerging targets such as CLDN18.2, B7-H3, FOLR1, and HER3 are rapidly gaining momentum, signaling a shift in ADC development from established targets to a highly competitive multi-target landscape.

Blog , 2026-06-23